RxDoctor Payments Data

Steven Cummings, MD

Internal Medicine · Stillwater, OKNPI 1750365292

Payments from drug & device makers

$542in general payments, 2019–2025

Across 27 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$94
  • Amgen$93
  • Sumitomo Pharma America, Inc.$62
  • Astellas Pharma US Inc$58
  • Novo Nordisk$37
  • Boehringer Ingelheim$37
  • plus $161 from 9 others

What the payments were for

  • Food & beverage$53098%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$542 in reported general payments places this provider in the 60th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$456,525
Medicare patients
1,404
Services billed
9,287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide237$251,553
MounjaroTirzepatide188$208,366
EliquisApixaban189$159,348
JardianceEmpagliflozin135$114,335
JanuviaSitagliptin Phosphate116$96,313
TrulicityDulaglutide62$76,138
Trelegy ElliptaFluticasone/Umeclidin/Vilanter78$64,599
XareltoRivaroxaban67$57,973
MyrbetriqMirabegron58$46,192
FarxigaDapagliflozin Propanediol40$36,739
Tresiba Flextouch U-200Insulin Degludec25$29,119
Breztri AerosphereBudesonide/Glycopyr/Formoterol35$29,057
ViberziEluxadoline16$25,882
Spiriva HandihalerTiotropium Bromide26$25,571
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog71$24,081

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$12$284,504250 claims
Novo NordiskOzempic$37$251,553237 claims
PfizerEliquis$19$159,348189 claims
Boehringer IngelheimJardiance, Trijardy Xr, Tradjenta, Glyxambi, Synjardy$37$149,021192 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$15$77,873106 claims
GSKTrelegy Ellipta, Breo Ellipta$94$74,344104 claims
Johnson & JohnsonXarelto$14$57,97367 claims
Astellas Pharma US IncMyrbetriq$58$46,19258 claims
NovartisEntresto$17$13,50814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Stillwater

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →